Dermatology Times, Managing Psoriasis With Biologics in the Medicare-Aged Patient Population, October 2025 (Vol. 46. Supp. 06)

Experts in Miami Beach emphasized that adherence often drives biologic choice more than efficacy in real-world psoriasis care.

Roundtable participants agreed the art of psoriasis management lies in aligning biologic or oral options with patient comorbidities, lifestyle, and insurance coverage.

Omar Noor leads a dynamic discussion on personalized psoriasis therapy, addressing patient challenges and innovative treatment options.

Tildrakizumab, HCP-administered biologics, and lifestyle-based decision-making took center stage in an interactive discussion led by Omar Noor, MD, FAAD, and colleagues.

At a recent Dermatology Times Case-Based Roundtable event, David Cotter, MD, PhD, reviewed treatment considerations for older patients with moderate to severe PsO who are candidates for biologic therapy.